CN119215164A - 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂 - Google Patents

用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂 Download PDF

Info

Publication number
CN119215164A
CN119215164A CN202411206189.XA CN202411206189A CN119215164A CN 119215164 A CN119215164 A CN 119215164A CN 202411206189 A CN202411206189 A CN 202411206189A CN 119215164 A CN119215164 A CN 119215164A
Authority
CN
China
Prior art keywords
adm
antibody
disease
scaffold
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411206189.XA
Other languages
English (en)
Chinese (zh)
Inventor
安德里斯·贝格曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adrenomed AG
Original Assignee
Adrenomed AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed AG filed Critical Adrenomed AG
Publication of CN119215164A publication Critical patent/CN119215164A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
CN202411206189.XA 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂 Pending CN119215164A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17192999 2017-09-25
EP17192999.5 2017-09-25
EP17203370 2017-11-23
EP17203370.6 2017-11-23
CN201880062062.1A CN111511390B (zh) 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
PCT/EP2018/075987 WO2019057992A2 (en) 2017-09-25 2018-09-25 ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880062062.1A Division CN111511390B (zh) 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂

Publications (1)

Publication Number Publication Date
CN119215164A true CN119215164A (zh) 2024-12-31

Family

ID=63722372

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411206189.XA Pending CN119215164A (zh) 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂
CN201880062062.1A Active CN111511390B (zh) 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880062062.1A Active CN111511390B (zh) 2017-09-25 2018-09-25 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂

Country Status (22)

Country Link
US (1) US20220227854A1 (enExample)
EP (5) EP3854414A1 (enExample)
JP (1) JP7461875B2 (enExample)
KR (2) KR20200088302A (enExample)
CN (2) CN119215164A (enExample)
AU (2) AU2018335438B2 (enExample)
BR (1) BR112020005450A2 (enExample)
CA (1) CA3076691A1 (enExample)
DK (1) DK3687567T3 (enExample)
ES (1) ES3001197T3 (enExample)
FI (1) FI3687567T3 (enExample)
HR (1) HRP20241795T1 (enExample)
HU (1) HUE069945T2 (enExample)
IL (1) IL273533A (enExample)
LT (1) LT3687567T (enExample)
MX (1) MX2020003538A (enExample)
MY (1) MY204700A (enExample)
PL (1) PL3687567T3 (enExample)
RS (1) RS66415B1 (enExample)
SG (1) SG11202002258WA (enExample)
SI (1) SI3687567T1 (enExample)
WO (1) WO2019057992A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114556100A (zh) 2019-08-30 2022-05-27 4Teen4制药有限公司 用于治疗休克的疗法指引和/或疗法监测
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
JP2023515042A (ja) * 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト ショックの治療若しくは予防において使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
US20210285949A1 (en) * 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN111893085A (zh) * 2020-08-04 2020-11-06 北京臻溪谷医学研究中心（有限合伙） 一种通过干细胞体外分化获得人工皮肤的方法及其应用
EP4559936A1 (en) * 2022-07-20 2025-05-28 Shanghai Jeyou Pharmaceutical Co., Ltd. Anti-adrenomedulin non-neutralizing antibody, method for preparing same, and use thereof
WO2025152915A1 (zh) * 2024-01-16 2025-07-24 上海济煜医药科技有限公司 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2457520A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2580881A1 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag Use of microproteins as tryptase inhibitors
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
ES2609043T3 (es) * 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
PT3553084T (pt) * 2011-11-16 2023-02-17 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
PT2594588E (pt) * 2011-11-16 2014-08-28 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
HUE032648T2 (en) * 2011-11-16 2017-10-30 Sphingotec Gmbh Adrenomedullin assays and procedures for determining the concentration of mature adrenomedullin
SG11201402362VA (en) * 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
US10598674B2 (en) * 2013-03-20 2020-03-24 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
MX2019007107A (es) * 2016-12-16 2019-10-21 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.

Also Published As

Publication number Publication date
WO2019057992A3 (en) 2019-05-02
RS66415B1 (sr) 2025-02-28
SI3687567T1 (sl) 2025-03-31
JP2020535151A (ja) 2020-12-03
FI3687567T3 (fi) 2025-01-08
RU2020114429A (ru) 2021-10-27
ES3001197T3 (es) 2025-03-04
EP3687567A2 (en) 2020-08-05
EP4159230A1 (en) 2023-04-05
LT3687567T (lt) 2025-02-10
AU2018335438B2 (en) 2025-08-21
EP3687567B1 (en) 2024-11-06
JP7461875B2 (ja) 2024-04-04
WO2019057992A2 (en) 2019-03-28
CN111511390A (zh) 2020-08-07
KR20250004928A (ko) 2025-01-08
BR112020005450A2 (pt) 2020-09-29
IL273533A (en) 2020-05-31
DK3687567T3 (da) 2024-12-16
EP4159229A1 (en) 2023-04-05
EP4488295A2 (en) 2025-01-08
CN111511390B (zh) 2024-09-20
HRP20241795T1 (hr) 2025-03-14
MY204700A (en) 2024-09-10
PL3687567T3 (pl) 2025-04-07
AU2023201479A1 (en) 2023-04-13
CA3076691A1 (en) 2019-03-28
US20220227854A1 (en) 2022-07-21
AU2018335438A1 (en) 2020-04-09
SG11202002258WA (en) 2020-04-29
EP4488295A3 (en) 2025-04-23
KR20200088302A (ko) 2020-07-22
HUE069945T2 (hu) 2025-04-28
EP3854414A1 (en) 2021-07-28
MX2020003538A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
CN111511390B (zh) 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
JP6321545B2 (ja) 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6321544B2 (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6224608B2 (ja) 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6193871B2 (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6193872B2 (ja) 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
KR20130060264A (ko) 위장관의 기능적 질환 또는 이상을 치료하는 제약학적 복합 조성물 및 방법들
RU2790561C2 (ru) Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания
HK40083955A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40120349A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40085254A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40058594A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40032645A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40032645B (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
HK40006910A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or ant-adm non-ig scaffold for use in therapy
CA2807529A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120923

Country of ref document: HK